Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma

Elisabetta Cenni; Francesca Perut; Donatella Granchi; Sofia Avnet; Ilaria Amato; Maria Luisa Brandi; Armando Giunti; Nicola Baldini

Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma

Elisabetta Cenni, Francesca Perut, Donatella Granchi, Sofia Avnet, Ilaria Amato, Maria Luisa Brandi, Armando Giunti, Nicola Baldini

Istituti Ortopedici Rizzoli

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Fibroblast growth factor-2 (FGF-2) has a role in the angiogenesis induced by renal carcinoma. Materials and Methods: Blockage of FGF-2 by an antisense oligonucleotide (ASO) or by a mouse neutralizing anti-human FGF-2 monoclonal antibody (anti-FGF-2-mAb) was evaluated on a cell line isolated from a renal carcinoma bone metastasis (CRBM-1990), on Caki-1 and ACHN cells. Cocultures of endothelial cells and ASO- or mAb-treated carcinoma lines were investigated. Results: Anti-FGF-2-mAb treatment induced a 33% reduction of FGF-2 released by ACHN, a 31% reduction of FGF-2 released by Caki-1, and a 70% reduction of FGF-2 released by CRBM-1990. ASO treatment did not inhibit endothelial cell proliferation. In contrast, anti-FGF-2-mAb significantly decreased endothelial cells proliferation induced by ACHN and CRBM-1990. The inhibition of endothelial cell growth was reverted by recombinant FGF-2. Conclusion: Modulation of FGF-2 production by renal cell carcinoma with a blocking mAb produced a significant inhibition of endothelial cell growth.

Original language	English
Pages (from-to)	315-320
Number of pages	6
Journal	Anticancer Research
Volume	27
Issue number	1 A
Publication status	Published - Jan 2007

Keywords

Angiogenesis
Antisense oligodeoxynucleotide
Bone metastasis
Fibroblast growth factor-2
Neutralizing antibody
Renal cell carcinoma

ASJC Scopus subject areas

Cancer Research
Oncology

Fingerprint Dive into the research topics of 'Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this

Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma. / Cenni, Elisabetta; Perut, Francesca ; Granchi, Donatella ; Avnet, Sofia; Amato, Ilaria; Brandi, Maria Luisa; Giunti, Armando; Baldini, Nicola.

In: Anticancer Research, Vol. 27, No. 1 A, 01.2007, p. 315-320.

Research output: Contribution to journal › Article › peer-review

@article{28e7a775de0b49a9a61504ec9a6e43fd,

title = "Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma",

abstract = "Background: Fibroblast growth factor-2 (FGF-2) has a role in the angiogenesis induced by renal carcinoma. Materials and Methods: Blockage of FGF-2 by an antisense oligonucleotide (ASO) or by a mouse neutralizing anti-human FGF-2 monoclonal antibody (anti-FGF-2-mAb) was evaluated on a cell line isolated from a renal carcinoma bone metastasis (CRBM-1990), on Caki-1 and ACHN cells. Cocultures of endothelial cells and ASO- or mAb-treated carcinoma lines were investigated. Results: Anti-FGF-2-mAb treatment induced a 33% reduction of FGF-2 released by ACHN, a 31% reduction of FGF-2 released by Caki-1, and a 70% reduction of FGF-2 released by CRBM-1990. ASO treatment did not inhibit endothelial cell proliferation. In contrast, anti-FGF-2-mAb significantly decreased endothelial cells proliferation induced by ACHN and CRBM-1990. The inhibition of endothelial cell growth was reverted by recombinant FGF-2. Conclusion: Modulation of FGF-2 production by renal cell carcinoma with a blocking mAb produced a significant inhibition of endothelial cell growth.",

keywords = "Angiogenesis, Antisense oligodeoxynucleotide, Bone metastasis, Fibroblast growth factor-2, Neutralizing antibody, Renal cell carcinoma",

author = "Elisabetta Cenni and Francesca Perut and Donatella Granchi and Sofia Avnet and Ilaria Amato and Brandi, {Maria Luisa} and Armando Giunti and Nicola Baldini",

year = "2007",

month = jan,

language = "English",

volume = "27",

pages = "315--320",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "1 A",

}

TY - JOUR

T1 - Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma

AU - Cenni, Elisabetta

AU - Perut, Francesca

AU - Granchi, Donatella

AU - Avnet, Sofia

AU - Amato, Ilaria

AU - Brandi, Maria Luisa

AU - Giunti, Armando

AU - Baldini, Nicola

PY - 2007/1

Y1 - 2007/1

N2 - Background: Fibroblast growth factor-2 (FGF-2) has a role in the angiogenesis induced by renal carcinoma. Materials and Methods: Blockage of FGF-2 by an antisense oligonucleotide (ASO) or by a mouse neutralizing anti-human FGF-2 monoclonal antibody (anti-FGF-2-mAb) was evaluated on a cell line isolated from a renal carcinoma bone metastasis (CRBM-1990), on Caki-1 and ACHN cells. Cocultures of endothelial cells and ASO- or mAb-treated carcinoma lines were investigated. Results: Anti-FGF-2-mAb treatment induced a 33% reduction of FGF-2 released by ACHN, a 31% reduction of FGF-2 released by Caki-1, and a 70% reduction of FGF-2 released by CRBM-1990. ASO treatment did not inhibit endothelial cell proliferation. In contrast, anti-FGF-2-mAb significantly decreased endothelial cells proliferation induced by ACHN and CRBM-1990. The inhibition of endothelial cell growth was reverted by recombinant FGF-2. Conclusion: Modulation of FGF-2 production by renal cell carcinoma with a blocking mAb produced a significant inhibition of endothelial cell growth.

AB - Background: Fibroblast growth factor-2 (FGF-2) has a role in the angiogenesis induced by renal carcinoma. Materials and Methods: Blockage of FGF-2 by an antisense oligonucleotide (ASO) or by a mouse neutralizing anti-human FGF-2 monoclonal antibody (anti-FGF-2-mAb) was evaluated on a cell line isolated from a renal carcinoma bone metastasis (CRBM-1990), on Caki-1 and ACHN cells. Cocultures of endothelial cells and ASO- or mAb-treated carcinoma lines were investigated. Results: Anti-FGF-2-mAb treatment induced a 33% reduction of FGF-2 released by ACHN, a 31% reduction of FGF-2 released by Caki-1, and a 70% reduction of FGF-2 released by CRBM-1990. ASO treatment did not inhibit endothelial cell proliferation. In contrast, anti-FGF-2-mAb significantly decreased endothelial cells proliferation induced by ACHN and CRBM-1990. The inhibition of endothelial cell growth was reverted by recombinant FGF-2. Conclusion: Modulation of FGF-2 production by renal cell carcinoma with a blocking mAb produced a significant inhibition of endothelial cell growth.

KW - Angiogenesis

KW - Antisense oligodeoxynucleotide

KW - Bone metastasis

KW - Fibroblast growth factor-2

KW - Neutralizing antibody

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=33847631768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847631768&partnerID=8YFLogxK

M3 - Article

C2 - 17352248

AN - SCOPUS:33847631768

VL - 27

SP - 315

EP - 320

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 A

ER -